发明名称 |
Delayed release, oral dosage compositions that contain amorphous CDDO-Me |
摘要 |
Pharmaceutical formulations exhibit a desirably low Cmax, among other properties, that contain particles of amorphous bardoxolone methyl, either in pure form or in the form of a solid dispersion, admixed with particles of a hydrophilic binding agent. Such formulations possess the advantage of higher oral bioavailability, relative to formulations based on the crystalline form of bardoxolone methyl. |
申请公布号 |
US8747901(B2) |
申请公布日期 |
2014.06.10 |
申请号 |
US201013201398 |
申请日期 |
2010.02.12 |
申请人 |
Reata Pharmaceuticals, Inc. |
发明人 |
Zhang Jiang;Meyer Colin J. |
分类号 |
A61K9/16;A61K9/50 |
主分类号 |
A61K9/16 |
代理机构 |
|
代理人 |
|
主权项 |
1. A solid dosage form comprising (A) particles consisting of amorphous bardoxolone methyl and a glass-forming excipient admixed with (B) particles consisting of hydroxypropyl methyl cellulose, wherein said particles (A) constitute a therapeutically effective amount of bardoxolone methyl.
|
地址 |
Irving TX US |